Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Therapy With High-Low Dose Radiotherapy Combined With Anti-PD-1 Monoclonal Antibody Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Single-Center Phase II Trial

NCT07277764 is registered in ClinicalTrials.gov with Jiangxi Provincial Cancer Hospital as lead sponsor.

NCT NCT07277764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07277764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Therapy With High-Low Dose Radiotherapy Combined With Anti-PD-1 Monoclonal Antibody Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Single-Center Phase II Trial
Lead sponsor
Jiangxi Provincial Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 10, 2025
Completion date
December 31, 2029
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma (npc), recurrent nasopharyngeal neoplasms